UK markets open in 2 hours 34 minutes

Calliditas Therapeutics AB (publ) (0A5R.L)

LSE - LSE Delayed price. Currency in SEK
Add to watchlist
110.00+4.90 (+4.66%)
At close: 05:02PM BST
Currency in SEK

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.39
52-week change 3-8.90%
S&P500 52-week change 323.57%
52-week high 3141.89
52-week low 30.00
50-day moving average 3115.78
200-day moving average 3100.71

Share statistics

Avg vol (3-month) 317.62k
Avg vol (10-day) 37.5k
Shares outstanding 5N/A
Implied shares outstanding 6N/A
Float 837.48M
% held by insiders 116.80%
% held by institutions 140.55%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -38.63%
Operating margin (ttm)5.37%

Management effectiveness

Return on assets (ttm)-12.81%
Return on equity (ttm)-84.68%

Income statement

Revenue (ttm)1.21B
Revenue per share (ttm)22.49
Quarterly revenue growth (yoy)5.20%
Gross profit (ttm)N/A
EBITDA -386.35M
Net income avi to common (ttm)-466.18M
Diluted EPS (ttm)-11.21
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)973.73M
Total cash per share (mrq)18.14
Total debt (mrq)979.13M
Total debt/equity (mrq)292.45%
Current ratio (mrq)3.13
Book value per share (mrq)6.24

Cash flow statement

Operating cash flow (ttm)-434.66M
Levered free cash flow (ttm)-292.03M